Health Care/Hospital
Oral report | The positive interim analysis results from the Phase III clinical study of Akeso's Cadonilimab (PD-1/CTLA-4 BsAb) plus chemotherapy as first-line treatment for advanced gastric cancer presented at 2024 AACR
SAN DIEGO, April 8, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced thatthe positive interim analysis results from Phase III clinical study of Cadonilimab (PD-1/CTLA-4 BsAb)combined with XELOX (capecitabine plus oxaliplatin) as first-line treatment for unresectable locally advanced or ...
2024-04-09 04:53
2069
Nano Labs Files Annual Report on Form 20-F for Fiscal Year 2023
HANGZHOU, China, April 8, 2024 /PRNewswire/ -- Nano Labs Ltd (Nasdaq: NA) ("we," the "Company" or "Nano Labs"), a leading fabless integrated circuit design company and product solution provider inChina, announced today that it filed its annual report on Form 20-F for the fiscal year endedDecember...
2024-04-09 04:45
3323
MAIWEIJIAN, First Approved Biosimilar of Denosumab (120mg) in China
SHANGHAI, April 8, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Denosumab Injection (trade name: MAIWEIJIAN, R&D code: 9MW0321) developed by its wholly-owned subsidiary T-mab has officially obtained the market...
2024-04-08 22:00
1443
Lunit's AI Demonstrates Up to 70% Workload Reduction and Enhanced Accuracy in Breast Cancer Screening: Study in European Radiology Reveals
- Employing Lunit INSIGHT MMG, a Turkish study showcases 70% efficiency improvements, advancements in early cancer detection, and interval cancer detection in mammography SEOUL, South Korea, April 8, 2024 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cance...
2024-04-08 21:00
1841
Medit Unveils i900: The Next Evolution of Intraoral Scanners
Secure a front-row seat for the debut of Medit i900 and discover the latest
cutting-edge dental technology
SEOUL, South Korea and LONG BEACH, Calif., April 8, 2024 /PRNewswire/ --
Medit (www.medit.com
2024-04-08 21:00
1411
SeekIn Presents New OncoSeek® Data at the AACR Annual Meeting in San Diego
Two Sample Types, Three Different Platforms, Six Independent Cohorts of ~12,000 Cancer Patients and Non-cancer Individuals with Diverse Ethnic Backgrounds in Retrospective and Prospective Settings Validate OncoSeek's Ability to Detect Multiple Cancer Types and Predict the Tissue of Origin of Ca...
2024-04-08 20:00
1250
D3 Bio Completes Series A+ Round to Advance Innovative Oncology Pipeline
SHANGHAI, April 8, 2024 /PRNewswire/ -- D3 Bio, an emerging global biotechnology company that focuses on discovery, development, and registration of innovative cancer drugs announces its closing of Series A+ financing round led by Medicxi, a leading European life sciences investment firm. D3 Bio'...
2024-04-08 15:00
1386
Laekna Announces Two Poster Presentations on Internally Discovered Drug Candidates at AACR 2024
SHANGHAI and WARREN, N.J., April 7, 2024 /PRNewswire/ -- Laekna (2105.HK) announced that the company has presented two internally-discovered preclinical candidates, in addition to a poster presentation on a clinical trial, at the 2024 Annual Meeting of the American Association for Cancer Research...
2024-04-08 08:30
1248
AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting
ROCKVILLE, Md. and SUZHOU, China, April 7, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced today that it releases the latest results from three pre...
2024-04-08 07:58
1482
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
ROCKVILLE, Md., April 5, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at th...
2024-04-05 19:00
1917
IASO Bio Announces U.S. FDA Approval of Investigational New Drug Application for BCMA CAR-T Equecabtagene Autoleucel for Generalized Myasthenia Gravis
SHANGHAI and NANJING, CHINA, and SAN JOSE, Calif., April 4, 2024 /PRNewswire/ -- IASO Biotechnology ("IASO Bio"), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, is pleased to announce that the Inve...
2024-04-05 08:00
1832
Datasea Enters into a Sales Agreement for its Acoustic Products Bringing its Evolutionary Technology to Market in a Strategic Milestone to Develop Rapid Online Sales
BEIJING, April 4, 2024 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), a digital technology company incorporated inNevada, dedicated to innovative business in acoustic high tech and 5G-Artificial Intelligence multimodal communication technology inthe United States and C...
2024-04-04 22:00
2035
Huahui Health to Present Preclinical Data of HH018-sesutecan at the 2024 AACR Annual Meeting
BEIJING, April 4, 2024 /PRNewswire/ -- Huahui Health Ltd.("Huahui Health"), a clinical stage biotechnology company focused on discovering and developing virology, hepatology, and oncology therapies, announced that it will present the results of preclinical data of HH018-sesutecan, a tumor microen...
2024-04-04 22:00
1716
China Medical University Hospital (CMUH) Ranked Global No.1 Smart Hospital in HIMSS Digital Health Indicator 2023
CMUH has been awarded DHI top hospitals twice in a row TAICHUNG, Taiwan, April 4, 2024 /PRNewswire/ -- China Medical University Hospital (CMUH) has achieved a global top score, 370/400, for the Healthcare Information and Management Systems Society (HIMSS) Digital Health Indicator（DHI）in 2023. T...
2024-04-04 20:30
2530
China Medical University Hospital (CMUH) Explores ' BrainHealth ' to Scrutinize Dementia within a Minute
TAICHUNG, Taiwan, April 4, 2024 /PRNewswire/ -- In clinical practice, neurologists scrutinize dementia patients with using numerous tools, including medical history, blood tests, cognitive testing, mental assessment, medical imaging and electro-physiological signal testing. Patients usually spend...
2024-04-04 20:30
2856
SYNPET to Showcase Innovative Postbiotic Solutions at Petfood Forum 2024
TAIPEI, April 3, 2024 /PRNewswire/ -- SYNPET, a subsidiary brand of SYNBIO TECH, a leading lactobacillus manufacturer based inTaiwan, is proud to announce its participation at the upcoming Petfood Forum 2024. This premier event for pet food and pet treat manufacturers and industry suppliers will ...
2024-04-04 01:00
1527
China Medical University Hospital (CMUH) Launches "Intelligent Microbiome Evaluation- iME" to Detect Intestinal Bad Bacteria and Empowers Personalized Gut Health
Patients with diarrhea and cramps have benefited greatly from iME TAICHUNG, Taiwan, April 3, 2024 /PRNewswire/ -- Gastrointestinal (GI) examinations can be invasive or non-invasive. Stool tests (non-invasive) can be associated with limitations such as the amount of pathogens present being too ...
2024-04-03 20:30
1590
CMUH (Taiwan) Launches "Intelligent Sepsis Early Prediction System (ISEPS)," Detecting Sepsis in One Minute Only
It is the world's first AI-Powered sepsis alert system to save more lives TAICHUNG, Taiwan, April 3, 2024 /PRNewswire/ -- In conventional practice, a blood culture report wouldn't be available until 18 to 72 hours later, rendering it non-feasible to facilitate rapid response. Led by Superintend...
2024-04-03 20:30
1647
China Medical University Hospital (CMUH) Inventing "Intelligent Urine Sediment Morphology Analysis, IUSMA" to Find Chronic Glomerulonephritis in Just 10 Minutes
TAICHUNG, Taiwan, April 3, 2024 /PRNewswire/ -- The urine sediment examination is primarily used to detect and assess kidney and urinary system health. In the conventional practice, a urine sediment test covers six items: red blood cells, white blood cells, squamous cells, urinary casts, crystals...
2024-04-03 20:30
1503
Ractigen Announces First Patient Dosed in the Phase I Clinical Trial of RAG-01 for NMIBC
JIANGSU, China, April 3, 2024 /PRNewswire/ -- Ractigen Therapeutics, a pioneer in small activating RNA (saRNA) therapeutics, achieved a major milestone today with the first patient dosed in its First-in-human phase I clinical trial for RAG-01 conducted in collaboration with GenesisCare,Australia'...
2024-04-03 20:00
1375
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
5310
